ISSN:
1432-5233
Schlagwort(e):
Acipimox
;
Free fatty acid
;
Very low density lipoprotein
;
Triglyceride
Quelle:
Springer Online Journal Archives 1860-2000
Thema:
Medizin
Notizen:
Abstract The mechanism of triglyceride lowering by Acipimox, a nicotinic acid analogue, was examined in a group of five moderately hypertriglyceridemic male rhesus monkeys. Two experiments were designed to examine the effect of the drug on lipid and glucose metabolism in nondiabetic, insulin-resistant animals. A single dose of Acipimox (8 mg/kg) given with a meal lowered the plasma free fatty acids (FFA) significantly at 4 h (0.102±0.008 vs 0.154±0.020 g/l; $$\bar x$$ ±SEM;P〈0.03); however, FFA concentrations returned to control levels at 6 h. Chronic administration of Acipimox (16 mg/kg q. i. d.) for 2 months produced a 31% reduction in triglyceride concentration (P〈0.05) and a significant decrease in low density lipoprotein (LDL)-cholesterol (P〈0.04), without changes in insulin action as measured by the hyperinsulinemic euglycemic clamp. Fasting FFA concentrations were not significantly altered by chronic treatment (0.163±0.013 versus 0.140±0.034 g/l). Fatty acid metabolic studies indicated increases in FFA transport (203.7±59.1 versus 136.1±26.6 μEq/min;P〈0.05), while FFA fractional clearance rate (FCR) was unchanged. Very low density lipoprotein triglyceride (VLDL-Tg) metabolic experiments, using [3H]glycerol, showed increases in production and FCR with the drug. Increased VLDL-Tg clearance, in spite of increased production of VLDL, appears to be the mechanism by which triglycerides are lowered upon chronic Acipimox administration.
Materialart:
Digitale Medien
URL:
http://dx.doi.org/10.1007/BF00576264
Permalink